We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Metal-on-Metal Hip Implants Should Be Banned

By HospiMedica International staff writers
Posted on 21 Mar 2012
A new study suggests that metal-on-metal (MOM) hip implants are more likely to fail than devices made from other materials, and should be banned.

Researchers at the University of Bristol (United Kingdom) analyzed data from the National Joint Registry of England and Wales, which includes information on more than 400,000 hip replacements, implanted between 2003 and 2011, and tracked them for up to seven years after surgery; of those, 31,171 were stemmed MOM implants. More...
The researchers estimated failure rates for the implants based on different head sizes and compared them with implants made from ceramic and polythene.

The researchers found that stemmed MOM implants failed much more quickly than other types of bearing surface, with a five-year revision rate of 6.2%. Failure was related to head size, with larger heads failing earlier, corresponding to a 2% increase in the risk of failure for each one mm increase in head size. By contrast, ceramic-on-ceramic implants did better with larger head sizes. In women, failure rates for stemmed MOM implants were up to four-times higher than those of other bearing surfaces, and were also higher compared with men, even with the same head size. The study was published early online on March 13, 2012, in the Lancet.

“Metal-on-metal stemmed articulations give poor implant survival compared with other options and should not be implanted,” concluded lead author Professor of orthopedic surgery Ashley Blom, MD, PhD, and colleagues. “All patients with these bearings should be carefully monitored, particularly young women implanted with large diameter heads.”

The leading cause of total hip replacement (THR) failure is aseptic loosening secondary to polyethylene wear. A second major cause of failure is dislocation, affecting about 4% of THRs, most within six months.

Surgeons and engineers have tried to address these problems by investigating alternative bearing surfaces that have lower wear and allow larger head sizes, which theoretically should lead to lower dislocation rates and improved implant survival. This, however, does not seem to be the case.

Related Links:

University of Bristol




Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Pressure Guidewire
SavvyWire
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.